Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.6252W HIGH $5.05
Volume
613.07 K
Value Traded
6.88 M
Short % Float
25.55%
+1.22%Week
-16.28%1 Month
-26.36%3 Month
+29.11%6 Month
-98.94%5 Year
-96.65%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
125.77 M
EPS (TTM)
-0.54
P/E Ratio
-
Ent. Value
99.09 M
Total Shares
43.30 M
Float Shares
38.26 M
Insiders
11.62%
Institutions
27.27%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
NRXP Catalyst Timeline
Dated clinical, regulatory and corporate events for NRX Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for NRX Pharmaceuticals, Inc.
635Total events
16Upcoming
179Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Trial InitiationNRX-101FiledTrial
SPARC-TMS trial to begin enrolling patients
Treatment Resistant Depressionsource ↗
▲Grant / FundingCorporate
NRx Defense Systems awarded $11.18M DARPA prime contract for SPARC-TMS trial
Treatment Resistant Depressionsource ↗
▲Major Amendment Submittedpreservative-free ketamineFiledRegulatory Filing
FDA reclassifies ANDA amendment for preservative-free ketamine from Major to Minor Amendment
▲Patent GrantedGNK-301IP / Competition
European Patent EP 3 570 878 B1 awarded for anti-HERV K Envelope antibody GNK-301
Amyotrophic Lateral Sclerosis (ALS)source ↗
●R&D DayPresentation
NRx participating in fireside chat at 2026 Cantor Global Healthcare Conference
●Oral PresentationPresentation
NRx Pharmaceuticals fireside chat at 2026 Cantor Global Healthcare Conference
◆Oral PresentationPresentation
NRx Pharmaceuticals to present at Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
●R&D DayPresentation
NRx management presentation at Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
●R&D DayPresentation
First annual 'HERVs and Humanity' conference at Princeton Institute for Advanced Study
●Manufacturing MilestoneGNK-301CMC / Inspection
GeNeuro initiated cGMP manufacture of GNK-301
Amyotrophic Lateral Sclerosis (ALS)source ↗
◆Oral PresentationPresentation
Conference call to discuss FDA first-cycle ANDA review and commercial plans
▲FDA Filing AcceptedNRX-100FiledRegulatory Filing
FDA completed first-cycle review of ANDA for preservative-free ketamine
suicidal ideation in depression, including bipolar depressionsource ↗
▲FDA Feedback ReceivedketamineFiledFDA Meeting
FDA completes first-cycle ANDA review with no drug-related major deficiencies
▲FDA Filing Acceptedpreservative-free ketamineFiledRegulatory Filing
FDA completes first-cycle ANDA review with no drug-related major deficiencies
▲FDA Feedback Receivedpreservative-free ketamineFiledFDA Meeting
FDA clarification meeting on ANDA remaining certification
▲Grant / FundingCorporate
GeNeuro selected in first round of CDMRP ALS grant competition for potential awards in Therapeutic and Biomarker Development
Amyotrophic Lateral Sclerosis (ALS)source ↗
●Timing GuidanceKETAFREE™FiledPresentation
Anticipated FDA decision on ANDA for Preservative-Free Ketamine in Q3 2026
preservative-free ketaminesource ↗
◆PDUFA DateNRX-100FiledRegulatory Filing
PDUFA decision date for NRX-100 ANDA
Suicidal ideation in Depressionsource ↗
◆FDA ApprovalKETAFREE™FiledFDA Decision
Anticipated FDA approval of preservative-free ketamine ANDA
▲Product LaunchNRX-100FiledPost-Market
Anticipated July 2026 launch of preservative-free ketamine
▲FDA ApprovalFDA Decision
Zeta TMS Robotic System receives FDA 510(k) clearance
transcranial magnetic stimulation (TMS)source ↗
▲Manufacturing MilestoneCMC / Inspection
Zeta TMS Robotic System received FDA 510(k) clearance
treatment-resistant depressionsource ↗
▲FDA Filing Acceptedpreservative-free ketamineFiledRegulatory Filing
Completed first-cycle FDA review of ANDA for preservative-free ketamine with no drug-related major deficiencies
▲Manufacturing Milestonepreservative-free ketamineFiledCMC / Inspection
Initiation of commercial scale manufacturing of preservative-free ketamine building to launch stock of 5 million doses
▲Partnership / LicenseNRX-101FiledCorporate
Selected by DARPA as prime contractor for SPARC-TMS trial of NRX-101 with robotic TMS
depressionsource ↗
▼Equity OfferingCorporate
Closed underwritten public offering of common stock for gross proceeds of $22.3 million
▲NDA SubmissionNRX-100FiledRegulatory Filing
Advancing NDA for NRX-100 on Real World Evidence from more than 65,000 patients
depressionsource ↗
▲Oral PresentationNRX-100FiledPresentation
Evidence from 65,000 patients presented at ASCP meeting in Miami
depressionsource ↗
▲Trial InitiationNRX-101FiledTrial
SPARC-TMS trial of NRX-101 with robotic TMS selected by DARPA
depressionsource ↗
▲First Patient DosedTrial
First patients treated with Zeta TMS Navigation System at HOPE Therapeutics clinics
Major Depressive Disorder and other CNS conditionssource ↗
▲IND ClearanceNRX-101FiledIND
FDA clearance of IND for SPARC-TMS trial combining NRX-101 with robotic neuronavigated TMS
suicidal depressionsource ↗
▼IP Litigation RulingIP / Competition
Kadima Neuropsychiatry Institute files suit against NRx Pharmaceuticals for breach of contract and misrepresentation
▲First Patient DosedTrial
First patient treated with Zeta TMS Navigation System at HOPE Therapeutics clinic
treatment-resistant depressionsource ↗
▲IND ClearanceNRX-101FiledIND
FDA approved Expanded Access Protocol for NRX-101 augmentation of TMS
Treatment-Resistant Depressionsource ↗
▲Trial InitiationNRX-101FiledTrial
Initiation of pivotal SPARC-TMS trial for NRX-101 augmentation of TMS
Treatment-Resistant Depression and Suicidalitysource ↗
▲Poster PresentationPresentation
Poster presentation of Real World Evidence comparing IV ketamine vs intranasal esketamine in depression
treatment resistant depressionsource ↗
◆Oral PresentationPresentation
Unveiling prototype robotic-enabled TMS with neuroplastic therapy at CTMSS 2026
depression, PTSDsource ↗
▼Equity OfferingCorporate
Pricing of underwritten public offering of 5,714,286 shares at $3.50 per share
●Timing GuidanceNRX-100FiledPresentation
NDA submission for NRX-100 planned
depression including suicidalitysource ↗
▲First Patient DosedTrial
HOPE became first US commercial site to treat patients with Zeta TMS Navigation System
●Manufacturing MilestoneGNK-301CMC / Inspection
GeNeuro initiated cGMP manufacture of GNK-301
Amyotrophic Lateral Sclerosis (ALS)source ↗
●Legal / SettlementCorporate
Assets of former Geneuro SA awarded to GeNeuro, Inc. by Courts of Switzerland
Past FDA Catalysts and PDUFA Decisions
How NRXP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | NRX-100 (KETAFREE™ / Preservative-Free Ketamine) | NDA Submission | NDA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D27 / 100
Pipeline Score
$13M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 79%
Micro Cap(rank 520 of 658)
Percentile Rank
NRX Pharmaceuticals, Inc. faces pipeline headwinds (27/100), with $224M risk-adjusted pipeline value, led by NRX-101 in Bipolar Depression (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NRX-101 Small moleculeCompletedNCT02974010 | Bipolar Depression | Phase 2 | COMPLETED | 104 | Nov 20, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every NRXP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IV ketamine Fast Track | treatment resistant depression | 2026-06-05 | remission rate iv: 34%; response rate iv: 63%; remission rate nasal esketamine: 26%; response rate nasal esketamine: 58%; odds ratio remission: 1.51; p value remission: <.001; odds ratio response: 1.22; p value response: <.003Read More | NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Javitt Jonathan CDirector, Officer (Chairman and Chief Scientist), 10% Owner | Buy | 40,000 84,634 held | $1.17 | 12/17/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in NRXP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NRXP for Q2 2026. | ||||
NRXP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NRXP ranks across every disease it competes in
Competitive Position is a premium feature
See how NRXP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNRXP News
NRXPNRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
NRx Defense Systems has secured an $11 million DARPA contract to evaluate a novel treatment for resistant depression using robotic TMS and NRX-101. The SPARC-TMS trial aims to validate a one-day treatment protocol that could revolutionize care for military personnel and others suffering from depression. This initiative builds on promising earlier studies showing significant treatment response rates.
Read more →NRXPNRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
NRx Pharmaceuticals has announced that the FDA has reclassified its ANDA amendment for preservative-free ketamine from a Major Amendment to a Minor Amendment. This change has also led to a revision of the GDUFA goal date to November 10, 2026. The company views this as a positive development that may facilitate a quicker approval process for their product.
Read more →NRXPGeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
GeNeuro, Inc. has been awarded a European Patent for GNK-301, a monoclonal antibody aimed at treating Amyotrophic Lateral Sclerosis (ALS). The patent covers the discovery that the HERV K Envelope protein is present in the spinal fluid of many ALS patients and is neurotoxic. The company plans to start Phase I trials in 2027, marking a significant step in ALS treatment development.
Read more →NRXPNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, is set to deploy the FDA-cleared Zeta TMS Robotic System, enhancing treatment precision for patients with depression. The clinical team is currently training in Boston, and the deployment will support the SPARC-TMS trial of NRX-101. This advancement aims to improve patient outcomes in both military and civilian settings.
Read more →NRXPNRx Pharmaceuticals to Participate in Upcoming Investor Conferences
NRx Pharmaceuticals will participate in three investor conferences in September 2026, showcasing its clinical-stage developments. CEO Jonathan Javitt will present at the Moody Capital Solutions Conference, the Cantor Global Healthcare Conference, and the H.C. Wainwright Global Investment Conference. The company is focused on developing therapies for central nervous system disorders.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
NRx Pharmaceuticals reported its financial results for Q2 2026, highlighting significant advancements in its drug development programs. The company completed the FDA review for preservative-free ketamine and initiated commercial manufacturing. Additionally, NRx was selected by DARPA for a Phase 2/3 trial of NRX-101, aiming for broader treatment applications. Financially, the company reported a net loss but secured substantial funding to support operations.
Read more →NRXP▼ -6.4%on this news
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
NRx Pharmaceuticals announced a conference call on August 10, 2026, to discuss the FDA's completion of the first-cycle review of its ANDA for preservative-free ketamine. Key executives will participate, addressing regulatory pathways and commercial plans. The call will be accessible via webcast and telephone, with a replay available afterward.
Read more →NRXP▲ +15.9%on this newsshared move
FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
NRx Pharmaceuticals announced that the FDA has completed the first-cycle review of its preservative-free ketamine ANDA, identifying no major deficiencies. The only remaining requirement is a certification related to the medication vial's luer lock tip. NRx views this outcome as a significant regulatory milestone that reduces risks for commercialization. A conference call is scheduled for August 10, 2026, to discuss further developments.
Read more →NRXPNRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
NRx Pharmaceuticals has responded to Kadima Neuropsychiatry Institute's recent allegations regarding a failed acquisition by HOPE Therapeutics. NRx has initiated arbitration due to Kadima's failure to meet key conditions. The company emphasizes its focus on drug development and innovative treatments, particularly in personalized medicine and TMS technology, despite the ongoing dispute.
Read more →NRXPNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, has initiated treatments using the FDA-cleared Zeta TMS Navigation System at its clinics in Florida. This marks a significant transition to active patient care, utilizing AI for precise targeting in TMS therapies for Major Depressive Disorder and other CNS conditions. The deployment supports HOPE's interventional psychiatry platform and aligns with planned clinical trials for NRX-101.
Read more →NRXPKadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition
Kadima Neuropsychiatry Institute has initiated legal proceedings against NRx Pharmaceuticals, claiming breach of contract and misrepresentation related to an acquisition. This lawsuit could have significant repercussions for NRx, potentially affecting its reputation and financial standing. The outcome of this case remains uncertain as it unfolds in the legal system.
Read more →NRXPZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics
ZETA SURGICAL and HOPE Therapeutics announced the successful treatment of the first patient using the Zeta TMS Navigation System, which is FDA-cleared. This system utilizes advanced AI and computer vision for precise targeting in TMS therapy, primarily for treatment-resistant depression. The technology aims to enhance patient outcomes and expand access to personalized care.
Read more →NRXPNRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
NRx Pharmaceuticals has received FDA approval for an Expanded Access Protocol for NRX-101, a combination of D-cycloserine and lurasidone, aimed at augmenting Transcranial Magnetic Stimulation (TMS) for patients with Treatment-Resistant Depression. This protocol allows patients who cannot participate in clinical trials to access the treatment. The company is also conducting a pivotal trial to assess the efficacy of NRX-101 in achieving remission from depression and suicidality.
Read more →NRXPNRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
NRx Pharmaceuticals announced a presentation at the American Society of Clinical Psychopharmacology, highlighting a study comparing IV ketamine and nasal esketamine for treating depression. The study found that IV ketamine resulted in higher remission and response rates among patients. However, it noted limitations due to non-randomized treatment assignments and potential confounding variables.
Read more →NRXPNRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
NRx Pharmaceuticals, Inc. has announced the successful closing of a public offering, raising approximately $22.3 million in gross proceeds. The funds are aimed at supporting working capital and general corporate purposes as the company continues its efforts in developing treatments for central nervous system disorders. The offering was completed following an effective shelf registration statement with the SEC. NRx's CEO emphasized the company's commitment to addressing critical mental health issues.
Read more →NRXP▼ -12.3%on this newsshared move
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
NRx Pharmaceuticals, Inc. has announced the pricing of a public offering of 5,714,286 shares of its common stock at $3.50 per share, aiming to raise approximately $20 million. The offering includes an option for underwriters to purchase additional shares, potentially increasing proceeds to $23 million. The funds will support working capital and corporate growth, with the offering expected to close on June 4, 2026.
Read more →NRXPNRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
NRx Pharmaceuticals, Inc. has announced a proposed public offering of its common stock to raise capital for working and corporate purposes. The offering will be underwritten, with a potential additional purchase option for the underwriter. The company has received designations for its therapeutic products aimed at treating central nervous system disorders, which may enhance its market position.
Read more →NRXPNRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026
NRx Pharmaceuticals, in collaboration with Emobot Health, presented clinical validation for EMOCARE, a smartphone-based tool for monitoring depression, at the ASCP 2026 meeting. The pooled analysis of three studies showed a 90% concordance with clinician-rated scales, indicating EMOCARE's effectiveness in tracking patient symptoms continuously. This innovation aims to enhance treatment monitoring in psychiatric care.
Read more →NRXPNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, has become the first commercial site to implement Zeta Surgical's FDA-cleared Zeta TMS Navigation System at its West Palm Beach clinic. This system will provide high-precision Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other neurological conditions. The deployment aligns with NRx's clinical trial plans for NRX-101, enhancing treatment options for patients.
Read more →NRXP▼ -5%on this news
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
NRx Pharmaceuticals reported its Q1 2026 financial results, highlighting significant progress in its drug development pipeline. The company anticipates an FDA decision on its ANDA for Preservative-Free Ketamine in Q3 2026 and has initiated commercial manufacturing. NRx also generated its first revenue from psychiatry clinics and appointed a new Chief Medical Innovation Officer. Despite a net loss, the company is optimistic about its growth and upcoming regulatory milestones.
Read more →About NRX Pharmaceuticals, Inc.
Headquarters1201 ORANGE STREET, WILMINGTON, DE, 19801
BIOPHARMAWATCH ELITE PLUS
Trade the next NRXP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime